09:59 AM EDT, 03/17/2025 (MT Newswires) -- Capricor Therapeutics ( CAPR ) said Monday its ongoing open label extension clinical trial for deramiocel showed a 52% reduction in the progression of Duchenne muscular dystrophy over a three-year period.

In a cohort-matched external comparator analysis, the study showed that patients treated with deramiocel over three years experienced an average decline of 3.46 points in Performance of the Upper Limb total score, compared to a 7.19-point decline in the external comparator group, the company said.

Deramiocel was also well tolerated with no new safety signals identified, the company said.

Capricor's Biologics License Application for deramiocel in cardiomyopathy related to Duchenne muscular dystrophy was recently accepted by the US Food and Drug Administration, with a target action date of Aug. 31.

Price: 13.48, Change: +0.25, Percent Change: +1.89